HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by GELFAND, M. M. Articles by FERENCZY, A. Search for Related Content PubMed PubMed Citation Articles by GELFAND, M. M. Articles by FERENCZY, A.

A Prospective 1-Year Study of Estrogen and Progestin in Postmenopausal Women: Effects on the Endometrium

From the Departments of Obstetrics and Gynecology and Pathology, The Sir Mortimer B. Davis Jewish General Hospital and McGill University, Montreal, Quebec, Canada

Abstract

The endometrial response to oral, cyclic conjugated equine estrogens with and without the randomized addition of medroxyprogesterone acetate was evaluated in 95 postmenopausal women with respect to morphology and bleeding patterns. At 1 year, therapy with 0.625 mg conjugated equine estrogens or 1.25 mg conjugated equine estrogens for 25 days of a 30-day cycle and 5 mg medroxyprogesterone acetate added to the last 11 days of the conjugated equine estrogens cycle was associated with hyperplasia in 0 and 10% of the patients, respectively (P=not significant). Hyperplasia developed in 30 and 57% of the patients who received the above conjugated equine estrogens and placebo regimens, respectively. Irregular, breakthrough bleeding occurred in 14% of the conjugated equine estrogens/ medroxyprogesterone acetate users and in 54% of the conjugated equine estrogens/placebo users. The results of this study indicate that 1 year of therapy with 0.625 mg conjugated equine estrogens and 5 mg medroxyprogesterone acetate provided the most satisfactory endometrial protection against hyperplasia and was associated with relatively low rates of breakthrough bleeding.

This article has been cited by other articles:

				H. Zang, L. Sahlin, B. Masironi, E. Eriksson, and A. Linden Hirschberg Effects of Testosterone Treatment on Endometrial Proliferation in Postmenopausal Women J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2169 - 2175. [Abstract] [Full Text] [PDF]

				G. E. Hale, C. L. Hughes, and J. M. Cline Endometrial Cancer: Hormonal Factors, the Perimenopausal ""Window of Risk,"" and Isoflavones J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 3 - 15. [Abstract] [Full Text] [PDF]

				K M Feeley and M Wells Hormone replacement therapy and the endometrium J. Clin. Pathol., June 1, 2001; 54(6): 435 - 440. [Abstract] [Full Text] [PDF]